Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Sepsis Care Breakthrough: Procalcitonin Tests Save Lives
University of Manchester researchers prove procalcitonin blood tests safely reduce antibiotic use in sepsis patients by two days, fighting resistance.
Merck in Talks to Acquire Revolution Medicines for $30B
Merck & Co. explores a potential $28-$32 billion acquisition of Revolution Medicines to bolster its oncology pipeline with targeted RAS inhibitors.
TMZ & EdU Combination Therapy
UNC researchers discover a synergistic combination of TMZ and EdU that kills glioblastoma cells while sparing healthy tissue. A potential shift in brain cancer R&D.
Clinical Trials in Indonesia: Strengthening the Ecosystem 2025
Indonesia partners with WHO to expand clinical trial capacity. Learn about the 83% growth in research activity and the new 2026-2027 roadmap for global trials.
The FDA Reform Test: Deregulation vs. Rare Disease Pathways
Exploring the FDA's 2025 reforms under HHS leadership. Will new pathways for PDCD and DCA lead to genuine deregulation or regulatory capture?
FDA Approves Mitapivat: First Oral Pill for Thalassemia
US FDA approves mitapivat (Aqvesme), the first oral pyruvate kinase activator for alpha- and beta-thalassemia. A breakthrough in treating chronic anemia.
Valneva Resumes Control of Ixchiq Vaccine Supply in Asia
Valneva terminates license agreement with Serum Institute of India (SII) to take direct control of Ixchiq chikungunya vaccine supply and commercialization.
BioAtla & GATC Health: Oz-V Phase III Oncology Trial
BioAtla and GATC Health partner to advance Ozuriftamab vedotin (Oz-V) into Phase III trials for OPSCC. Explore the $40M SPV transaction and AI-driven drug discovery.
GLP-1 Agonists: Neuroprotection & Dementia Prevention Study
New Karolinska Institutet research shows GLP-1 agonists reduce dementia risk by 30%. Discover neuro-metabolic drug discovery targets at ChemDiv.
10
11
12
13
14
